Long‐term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib

Bosutinib is an Src/Abl tyrosine kinase inhibitor (TKI) indicated for adults with Ph+ chronic myeloid leukemia (CML) resistant/intolerant to prior TKIs. This long‐term update of an ongoing phase 1/2 study evaluated the efficacy and safety of third‐/fourth‐line bosutinib in adults with chronic phase...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Am J Hematol
Hoofdauteurs: Cortes, Jorge E., Khoury, Hanna J., Kantarjian, Hagop M., Lipton, Jeff H., Kim, Dong‐Wook, Schafhausen, Philippe, Matczak, Ewa, Leip, Eric, Noonan, Kay, Brümmendorf, Tim H., Gambacorti‐Passerini, Carlo
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: John Wiley and Sons Inc. 2016
Onderwerpen:
Research Articles
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5303616/
https://ncbi.nlm.nih.gov/pubmed/27531525
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.24536
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items